Literature DB >> 22947141

Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.

Christopher S Morello1, Kimberly A Kraynyak1, Michael S Levinson2, Zhijiang Chen3, Kuo-Fen Lee3, Deborah H Spector1,2.   

Abstract

Herpes Simplex Virus Type 2 (HSV-2) infection can result in life-long recurrent genital disease, asymptomatic virus shedding, and transmission. No vaccine to date has shown significant protection clinically. Here, we used a mouse model of genital HSV-2 infection to test the efficacy of a vaccine consisting of whole, formalin-inactivated HSV-2 (FI-HSV2) formulated with monophosphoryl lipid A (MPL) and alum adjuvants. Vaccine components were administered alone or as a prime-boost immunization together with DNA vaccines encoding a truncated glycoprotein D2 (gD2t) and two conserved HSV-2 genes necessary for virus replication, UL5 (DNA helicase) and UL30 (DNA polymerase). Our results show: (1) compared with mock immunized controls, mice immunized with FI-HSV2 plus MPL/alum consistently showed protection against disease burden and total viral shedding while the mice immunized with gD2t protein with MPL/alum did not; (2) protection against genital disease and viral replication correlated with the type of boost in a prime-boost immunization with little advantage afforded by a DNA prime; (3) intramuscular (i.m.) immunization with FI-HSV2 in MPL/Alhydrogel adjuvant provided nearly complete protection against vaginal HSV-2 shedding after a lethal intravaginal (i.vag.) short-term challenge and long-term rechallenge; (4) single formulation immunization with DNA vaccines, FI-HSV2, and MPL in an aluminum phosphate (Adju-Phos) adjuvant did not increase protection relative to FI-HSV2/MPL/Adju-Phos alone; and (5) addition of MPL/alum to the FI-HSV2 was required for optimal protection against disease, viral replication, and latent virus load in the dorsal root ganglia (DRG). Most notably, an optimized vaccine formulation of FI-HSV2 MPL/Alhydrogel given i.m. completely protected against detectable vaginal HSV-2 shedding in the majority of animals and HSV-2 latent DNA in the DRG of all animals.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22947141      PMCID: PMC3754855          DOI: 10.1016/j.vaccine.2012.08.049

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  32 in total

1.  Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease.

Authors:  Christopher S Morello; Michael S Levinson; Kimberly A Kraynyak; Deborah H Spector
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

2.  Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.

Authors:  Sita Awasthi; Elizabeth E Zumbrun; Huaxin Si; Fushan Wang; Carolyn E Shaw; Michael Cai; John M Lubinski; Shana M Barrett; John W Balliet; Jessica A Flynn; Danilo R Casimiro; Janine T Bryan; Harvey M Friedman
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

3.  Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa.

Authors:  Timothy E Dudek; Ernesto Torres-Lopez; Clyde Crumpacker; David M Knipe
Journal:  J Infect Dis       Date:  2011-04-14       Impact factor: 5.226

4.  Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.

Authors:  Sita Awasthi; John M Lubinski; Carolyn E Shaw; Shana M Barrett; Michael Cai; Fushan Wang; Michael Betts; Susan Kingsley; Daniel J Distefano; John W Balliet; Jessica A Flynn; Danilo R Casimiro; Janine T Bryan; Harvey M Friedman
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

5.  Efficacy results of a trial of a herpes simplex vaccine.

Authors:  Robert B Belshe; Peter A Leone; David I Bernstein; Anna Wald; Myron J Levin; Jack T Stapleton; Iris Gorfinkel; Rhoda L Ashley Morrow; Marian G Ewell; Abbie Stokes-Riner; Gary Dubin; Thomas C Heineman; Joann M Schulte; Carolyn D Deal
Journal:  N Engl J Med       Date:  2012-01-05       Impact factor: 91.245

6.  Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models.

Authors:  Tansi Khodai; Debbie Chappell; Clare Christy; Paul Cockle; Jim Eyles; Daisy Hammond; Katrina Gore; Michael J McCluskie; Dana M Evans; Susanne Lang; Peter T Loudon; Tim Townend; Paul Wright; Kate West; Helen Bright
Journal:  Clin Vaccine Immunol       Date:  2011-08-18

7.  The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions.

Authors:  Joshua T Schiffer; Anna Wald; Stacy Selke; Lawrence Corey; Amalia Magaret
Journal:  J Infect Dis       Date:  2011-08-15       Impact factor: 5.226

8.  A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine.

Authors:  William P Halford; Ringo Püschel; Edward Gershburg; Andrew Wilber; Svetlana Gershburg; Brandon Rakowski
Journal:  PLoS One       Date:  2011-03-11       Impact factor: 3.240

9.  Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes.

Authors:  Timothy Dudek; Lydia C Mathews; David M Knipe
Journal:  Virology       Date:  2007-11-19       Impact factor: 3.616

Review 10.  Herpes simplex: insights on pathogenesis and possible vaccines.

Authors:  David M Koelle; Lawrence Corey
Journal:  Annu Rev Med       Date:  2008       Impact factor: 13.739

View more
  12 in total

1.  DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.

Authors:  Sachin Gupta; Emily S Clark; James M Termini; Justin Boucher; Saravana Kanagavelu; Celia C LeBranche; Sakhi Abraham; David C Montefiori; Wasif N Khan; Geoffrey W Stone
Journal:  J Virol       Date:  2015-01-28       Impact factor: 5.103

Review 2.  Recent advances in vaccine development for herpes simplex virus types I and II.

Authors:  Jeffrey L Coleman; Deepak Shukla
Journal:  Hum Vaccin Immunother       Date:  2013-02-26       Impact factor: 3.452

3.  Current status and prospects for development of an HSV vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  Vaccine       Date:  2013-09-06       Impact factor: 3.641

Review 4.  Vaccines to prevent genital herpes.

Authors:  Kevin Egan; Lauren M Hook; Philip LaTourette; Angela Desmond; Sita Awasthi; Harvey M Friedman
Journal:  Transl Res       Date:  2020-03-16       Impact factor: 7.012

5.  Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.

Authors:  Michael T Hensel; Jason D Marshall; Michael R Dorwart; Darren S Heeke; Eileen Rao; Padmaja Tummala; Li Yu; Gary H Cohen; Roselyn J Eisenberg; Derek D Sloan
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

6.  Impact of Type I Interferon on the Safety and Immunogenicity of an Experimental Live-Attenuated Herpes Simplex Virus 1 Vaccine in Mice.

Authors:  Derek J Royer; Meghan M Carr; Ana J Chucair-Elliott; William P Halford; Daniel J J Carr
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

7.  Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.

Authors:  Sita Awasthi; Jialing Huang; Carolyn Shaw; Harvey M Friedman
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

Review 8.  Prospects and perspectives for development of a vaccine against herpes simplex virus infections.

Authors:  Shane C McAllister; Mark R Schleiss
Journal:  Expert Rev Vaccines       Date:  2014-07-31       Impact factor: 5.217

9.  Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2.

Authors:  William P Halford; Joshua Geltz; Edward Gershburg
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

Review 10.  HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine.

Authors:  Xiao-Peng Zhu; Zaka S Muhammad; Jian-Guang Wang; Wu Lin; Shi-Kun Guo; Wei Zhang
Journal:  Viruses       Date:  2014-01-24       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.